RANKL promotes osteoblastic activity in vascular smooth muscle cells by upregulating endothelial BMP-2 release

International Journal of Biochemistry and Cell Biology

Volumn 77, Issue , 2016, Pages 171-180

  Davenport, Colin ^a   Harper, Emma ^a   Forde, Hannah ^a   Rochfort, Keith D ^b   Murphy, Ronan P ^a   Smith, Diarmuid ^c   Cummins, Philip M ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c BEAUMONT HOSPITAL   (Ireland)

Author keywords

BMP 2; Calcification; Endothelial; Osteoprotegerin; RANKL

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; MESSENGER RNA; NOGGIN; OSTEOCLAST DIFFERENTIATION FACTOR; TRANSCRIPTION FACTOR RUNX2; BMP2 PROTEIN, HUMAN;

AORTA ENDOTHELIUM; AORTA MEDIA; ARTICLE; BLOOD VESSEL CALCIFICATION; BONE DEVELOPMENT; COCULTURE; CONDITIONED MEDIUM; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN AORTIC ENDOTHELIAL CELL; HUMAN AORTIC SMOOTH MUSCLE CELL; HUMAN CELL; IN VITRO STUDY; MOLECULAR PATHOLOGY; MONOCULTURE; PARACRINE SIGNALING; PROTEIN FUNCTION; SHEAR FLOW; UPREGULATION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE CELL; ADULT; CYTOLOGY; DIAGNOSTIC IMAGING; DRUG EFFECTS; FEMALE; MALE; OSTEOBLAST; SECRETION (PROCESS); VASCULAR SMOOTH MUSCLE; YOUNG ADULT;

ADULT; BONE MORPHOGENETIC PROTEIN 2; ENDOTHELIAL CELLS; FEMALE; HUMANS; MALE; MUSCLE, SMOOTH, VASCULAR; OSTEOBLASTS; RANK LIGAND; YOUNG ADULT;

EID: 84977085829     PISSN: 13572725     EISSN: 18785875     Source Type: Journal    
DOI: 10.1016/j.biocel.2016.06.009     Document Type: Article

References (29)

1. Abedin, M., Tintut, Y., Demer, L.L., Vascular calcification: mechanisms and clinical ramifications. Arterioscler. Thromb. Vasc. Biol. 24 (2004), 1161–1170.
2. Bucay, N., Sarosi, I., Dunstan, C.R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H.L., Xu, W., Lacey, D.L., Boyle, W.J., Simonet, W.S., Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12:9 (1998), 1260–1268.
3. Byon, C.H., Chen, Y., Molecular mechanisms of vascular calcification in chronic kidney disease: the link between bone and the vasculature. Curr. Osteoporos. Rep. 13:4 (2015), 206–215.
4. Byon, C.H., Sun, Y., Chen, J., Yuan, K., Mao, X., Heath, J.M., Anderson, P.G., Tintut, Y., Demer, L.L., Wang, D., Chen, Y., Runx2-upregulated receptor activator of nuclear factor (B ligand in calcifying smooth muscle cells promotes migration and osteoclastic differentiation of macrophages. Arterioscler. Thromb. Vasc. Biol. 31:6 (2011), 1387–1396.
5. Candido, R., Toffoli, B., Corallini, F., Bernardi, S., Zella, D., Voltan, R., Grill, V., Celeghini, C., Fabris, B., Human full-length osteoprotegerin induces the proliferation of rodent vascular smooth muscle cells both in vitro and in vivo. J. Vasc. Res. 47:3 (2010), 252–261.
6. Chiu, J.J., Usami, S., Chien, S., Vascular endothelial responses to altered shear stress: pathologic implications for atherosclerosis. Ann. Med. 41 (2009), 19–28.
7. Cummings, S.R., San Martin, J., McClung, M.R., Siris, E.S., Eastell, R., Reid, I.R., Delmas, P., Zoog, H.B., Austin, M., Wang, A., Kutilek, S., Adami, S., Zanchetta, J., Libanati, C., Siddhanti, S., Christiansen, C., FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361:8 (2009), 756–765.
8. Davenport, C., Mahmood, W.A., Forde, H., Ashley, D.T., Agha, A., McDermott, J., Sreenan, S., Thompson, C.J., McGrath, F., McAdam, B., Cummins, P.M., Smith, D., The effects of insulin and liraglutide on osteoprotegerin and vascular calcification in vitro and in patients with type 2 diabetes. Eur. J. Endocrinol. 173:1 (2015), 55–61.
9. Demer, L.L., Tintut, Y., Vascular calcification: pathobiology of a multifaceted disease. Circulation 117 (2008), 2938–2948.
10. Eddahibi, S., Guignabert, C., Barlier-Mur, A.M., Dewachter, L., Fadel, E., Dartevelle, P., Humbert, M., Simonneau, G., Hanoun, N., Saurini, F., Hamon, M., Adnot, S., Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation 113:15 (2006), 1857–1864.
11. Higgins, C.L., Isbilir, S., Basto, P., Chen, I.Y., Vaduganathan, M., Vaduganathan, P., Reardon, M.J., Lawrie, G., Peterson, L., Morrisett, J.D., Distribution of alkaline phosphatase, osteopontin, RANK ligand and osteoprotegerin in calcified human carotid atheroma. Protein J. 34:5 (2015), 315–328.
12. Janke, D., Jankowski, J., Rüth, M., Buschmann, I., Lemke, H.D., Jacobi, D., Knaus, P., Spindler, E., Zidek, W., Lehmann, K., Jankowski, V., The artificial artery as in vitro perfusion model. PLoS One, 8(3), 2013, e57227.
13. Johnson, R.C., Leopold, J.A., Loscalzo, J., Vascular calcification: pathobiological mechanisms and clinical implications. Circ. Res. 99 (2006), 1044–1059.
14. Kaden, J.J., Bickelhaupt, S., Grobholz, R., Haase, K.K., Sarikoç, A., Kiliç, R., Brueckmann, M., Lang, S., Zahn, I., Vahl, C., Hagl, S., Dempfle, C.E., Borggrefe, M., Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J. Mol. Cell. Cardiol. 36:1 (2004), 57–66.
15. Krause, C., Guzman, A., Knaus, P., Noggin. Int. J. Biochem. Cell Biol. 43 (2011), 478–481.
16. Martin, F.A., McLoughlin, A., Rochfort, K.D., Davenport, C., Murphy, R.P., Cummins, P.M., Regulation of thrombomodulin expression and release in human aortic endothelial cells by cyclic strain. PLoS One, 9(9), 2014, e108254.
17. Moran, C.S., McCann, M., Karan, M., Norman, P., Ketheesan, N., Golledge, J., Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation 111 (2005), 3119–3125.
18. Morony, S., Tintut, Y., Zhang, Z., Cattley, R.C., Van, G., Dwyer, D., Stolina, M., Kostenuik, P.J., Demer, L.L., Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation 117:3 (2008), 411–420.
19. Olesen, M., Skov, V., Mechta, M., Mumm, B.H., Rasmussen, L.M., No influence of OPG and its ligands RANKL and TRAIL, on proliferation and regulation of the calcification process in primary human vascular smooth muscle cells. Mol. Cell. Endocrinol. 362 (2012), 149–156.
20. Osako, M.K., Nakagami, H., Koibuchi, N., Shimizu, H., Nakagami, F., Koriyama, H., Shimamura, M., Miyake, T., Rakugi, H., Morishita, R., Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification. Circ. Res. 107:4 (2010), 466–475.
21. Panizo, S., Cardus, A., Encinas, M., Parisi, E., Valcheva, P., López-Ongil, S., Coll, B., Fernandez, E., Valdivielso, J.M., RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ. Res. 104:9 (2009), 1041–1048.
22. Price, P.A., June, H.H., Buckley, J.R., Williamson, M.K., Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler. Thromb. Vasc. Biol. 21 (2001), 1610–1616.
23. Redmond, E.M., Cahill, P.A., Sitzmann, J.V., Perfused transcapillary smooth muscle and endothelial cell co-culture—a novel in vitro model. In vitro Cell. Dev. Biol. Anim. 31 (1995), 601–609.
24. Rochfort, K.D., Collins, L.E., Murphy, R.P., Cummins, P.M., Downregulation of blood-brain barrier phenotype by proinflammatory cytokines involves NADPH oxidase-dependent ROS generation: consequences for interendothelial adherens and tight junctions. PLoS One, 9(7), 2014, e101815.
25. Vitovski, S., Phillips, J.S., Sayers, J., Croucher, P.I., Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J. Biol. Chem. 282 (2007), 31601–31609.
26. Wexler, L., Brundage, B., Crouse, J., Detrano, R., Fuster, V., Maddahi, J., Rumberger, J., Stanford, W., White, R., Taubert, K., Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association. Writing Group. Circulation 94 (1996), 1175–1192.
27. Wu, M., Rementer, C., Giachelli, C.M., Vascular calcification: an update on mechanisms and challenges in treatment. Calcif. Tissue Int. 93:4 (2013), 365–373.
28. Yuan, L.Q., Zhu, J.H., Wang, H.W., Liang, Q.H., Xie, H., Wu, X.P., Zhou, H., Cui, R.R., Sheng, Z.F., Zhou, H.D., Zhu, X., Liu, G.Y., Liu, Y.S., Liao, E.Y., RANKL is a downstream mediator for insulin-induced osteoblastic differentiation of vascular smooth muscle cells. PLoS One, 6(12), 2011, e29037.
29. Zhang, J., Fu, M., Myles, D., Zhu, X., Du, J., Cao, X., Chen, Y.E., PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett. 521:1–3 (2002), 180–184.